(Q33346935)

English

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate (English)

1 reference

Europe PubMed Central

26 July 2017

0 references

12

object named as

E P Krenning

1 reference

Europe PubMed Central

26 July 2017

Dirk J. Kwekkeboom

1

object named as

D J Kwekkeboom

1 reference

Europe PubMed Central

26 July 2017

Jaap J M Teunissen

4

object named as

J J M Teunissen

1 reference

Europe PubMed Central

26 July 2017

Wouter W de Herder

6

object named as

W W de Herder

1 reference

Europe PubMed Central

26 July 2017

author name string

W H Bakker

2

1 reference

Europe PubMed Central

26 July 2017

B L Kam

3

1 reference

Europe PubMed Central

26 July 2017

P P M Kooij

5

1 reference

Europe PubMed Central

26 July 2017

R A Feelders

7

1 reference

Europe PubMed Central

26 July 2017

C H J van Eijck

8

1 reference

Europe PubMed Central

26 July 2017

M de Jong

9

1 reference

Europe PubMed Central

26 July 2017

A Srinivasan

10

1 reference

Europe PubMed Central

26 July 2017

J L Erion

11

1 reference

Europe PubMed Central

26 July 2017

publication date

9 January 2003

1 reference

Europe PubMed Central

26 July 2017

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

Europe PubMed Central

26 July 2017

30

1 reference

Europe PubMed Central

26 July 2017

417-422

1 reference

Europe PubMed Central

26 July 2017

3

1 reference

Europe PubMed Central

26 July 2017

https://scigraph.springernature.com/pub.10.1007/s00259-002-1050-8

0 references

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1998890

21 June 2018

In situ radiotherapy with 111In-pentetreotide: initial observations and future directions.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1998890

21 June 2018

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1998890

21 June 2018

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1998890

31 October 2018

Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1998890

31 October 2018

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1998890

31 October 2018

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1998890

31 October 2018

Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1998890

31 October 2018

[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1998890

31 October 2018

Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/12634971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/12634971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

1 reference

https://pubmed.ncbi.nlm.nih.gov/12634971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/12634971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00259-002-1050-8

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33346935&oldid=2001980908"